Drug ID: | NPD2290 |
Drug Name: | AS-3201 |
Molecular Formula: | C17H11BrFN3O4 |
Canonical SMILES: | OC1=NC(=O)[C@]2(C1)C(=O)N(Cc1ccc(cc1F)Br)C(=O)c1n2ccc1 |
Standard InCHI: | InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1 |
Standard InCHIKey: | QCVNMNYRNIMDKV-QGZVFWFLSA-N |
Max Developmental Stage: | Phase 3 |
Max Developmental Stage Source: | DrugBank |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
Tanimoto coefficient is calculated based on PubChem 881-bit substructure fingerprints.
High Similarity Level: Tc>=0.85; Intermediate Similarity Level: 0.7 <= Tc < 0.85; Remote Similarity Level: 0.65 <= Tc < 0.7
TTD | DNCL003522; DNCL002967 |
DrugBank | DB05327 |
ChEMBL | CHEMBL334830 |
IUPHAR/BPS | |
PharmaGKB | |
KEGG Drug | |
PubChem CID | 153948 |
ChEBI | |
CAS Number | 147254-64-6 |
Molecular Weight | 418.99 |
ALogP | -0.4664 |
MLogP | 2.34 |
XLogP | 1.894 |
HDA | 7 |
HBD | 1 |
Rotatable Bonds | 5 |
TPSA | 91.97 |
RO5 Violation | 0 |